Exact Mass: 656.3673

Exact Mass Matches: 656.3673

Found 385 metabolites which its exact mass value is equals to given mass value 656.3673, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Neomycin-LP-I

N3-Acetylneomycin

C25H48N6O14 (656.3228)


   

(2R)-2-[[(2R)-2-[[(2S)-2-(Azepane-1-carbonylamino)-4-methylpentanoyl]amino]-3-(1-formylindol-3-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoic acid

2-({2-[(2-{[(azepan-1-yl)(hydroxy)methylidene]amino}-1-hydroxy-4-methylpentylidene)amino]-3-(1-formyl-1H-indol-3-yl)-1-hydroxypropylidene}amino)-3-(1H-indol-3-yl)propanoate

C36H44N6O6 (656.3322)


   

PA(12:0/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/12:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/12:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(5Z,11Z,14Z)-O(8,9)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/12:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-(dodecanoyloxy)-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/12:0)

[(2R)-2-(dodecanoyloxy)-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(8Z,11Z,14Z)-O(5,6)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/12:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/12:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-3-(dodecanoyloxy)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/12:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/12:0)

C35H61O9P (656.4053)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/12:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/12:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,14Z,18S)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/12:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/12:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/12:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/12:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-3-(dodecanoyloxy)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/12:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-3-(dodecanoyloxy)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/12:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(12:0/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-3-(dodecanoyloxy)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(12:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(12:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one dodecanoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/12:0)

[(2R)-2-(dodecanoyloxy)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/12:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of dodecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/18:2(10E,12Z)+=O(9))

[(2R)-2-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(14:1(9Z)/18:2(10E,12Z)+=O(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/18:2(10E,12Z)+=O(9)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 9-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(10E,12Z)+=O(9)/14:1(9Z))

[(2R)-3-{[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(18:2(10E,12Z)+=O(9)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(10E,12Z)+=O(9)/14:1(9Z)), in particular, consists of one chain of one 9-oxo-octadecadienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/18:2(9Z,11E)+=O(13))

[(2R)-2-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(14:1(9Z)/18:2(9Z,11E)+=O(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/18:2(9Z,11E)+=O(13)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 13-oxo-octadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:2(9Z,11E)+=O(13)/14:1(9Z))

[(2R)-3-{[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(18:2(9Z,11E)+=O(13)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:2(9Z,11E)+=O(13)/14:1(9Z)), in particular, consists of one chain of one 13-oxo-octadecadienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/18:3(10,12,15)-OH(9))

[(2R)-2-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(14:1(9Z)/18:3(10,12,15)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/18:3(10,12,15)-OH(9)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 9-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(10,12,15)-OH(9)/14:1(9Z))

[(2R)-3-{[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(18:3(10,12,15)-OH(9)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(10,12,15)-OH(9)/14:1(9Z)), in particular, consists of one chain of one 9-hydroxyoctadecatrienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(14:1(9Z)/18:3(9,11,15)-OH(13))

[(2R)-2-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-3-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(14:1(9Z)/18:3(9,11,15)-OH(13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(14:1(9Z)/18:3(9,11,15)-OH(13)), in particular, consists of one chain of one 9Z-tetradecenoyl at the C-1 position and one chain of 13-hydroxyoctadecatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(18:3(9,11,15)-OH(13)/14:1(9Z))

[(2R)-3-{[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy}-2-[(9Z)-tetradec-9-enoyloxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(18:3(9,11,15)-OH(13)/14:1(9Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:3(9,11,15)-OH(13)/14:1(9Z)), in particular, consists of one chain of one 13-hydroxyoctadecatrienoyl at the C-1 position and one chain of 9Z-tetradecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/i-12:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/i-12:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:3(5Z,11Z,14Z)-O(8,9))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(5Z,11Z,14Z)-O(8,9)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/i-12:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-[(10-methylundecanoyl)oxy]-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/i-12:0)

[(2R)-2-[(10-methylundecanoyl)oxy]-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:3(8Z,11Z,14Z)-O(5,6)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/i-12:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/i-12:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/i-12:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/i-12:0)

[(2R)-3-{[(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/i-12:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/i-12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/i-12:0)

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/i-12:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/i-12:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,18S)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/i-12:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/i-12:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/i-12:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/i-12:0)

[(2R)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/i-12:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/i-12:0)

[(2R)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/i-12:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/i-12:0)

[(2R)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/i-12:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/i-12:0)

[(2R)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/i-12:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(i-12:0/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}-3-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(i-12:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-12:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one 10-methylundecanoyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/i-12:0)

[(2R)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}-2-[(10-methylundecanoyl)oxy]propoxy]phosphonic acid

C35H61O9P (656.4053)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/i-12:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/i-12:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of 10-methylundecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Monensin B

(2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-7-hydroxy-2-[(2R,5S)-5-[(2R,3S,5R)-5-[(3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3-methyloxolan-2-yl]-5-methyloxolan-2-yl]-2,8-dimethyl-1,10-dioxaspiro[4.5]decan-9-yl]-3-methoxy-2-methylpentanoic acid

C35H60O11 (656.4135)


Monensin B is a polyketide produced by Streptomyces cinnamonensis. Fermentations of Streptomyces cinnamonensis produce a mixture of Monensin A and Monensin B in a ratio dependent upon the relative concentrations of ethylmalonyl-CoA and methylmalonyl-CoA[1].

   
   

Russelioside C

Russelioside C

C34H56O12 (656.3772)


   
   

Isoeleutherobin A

Isoeleutherobin A

C35H48N2O10 (656.3309)


   

Wikstroelide B

Wikstroelide B

C37H52O10 (656.356)


   
   

Dysoxylin D

Dysoxylin D

C37H52O10 (656.356)


   
   

Russelioside A

Russelioside A

C34H56O12 (656.3772)


   

Chisonimbolinin A

Chisonimbolinin A

C36H48O11 (656.3196)


   

15-O-deacetylnimbolidin B

15-O-deacetylnimbolidin B

C36H48O11 (656.3196)


A tricyclic triterpenoid that is isolated from Melia azedarach and exhibits anticancer activity.

   

orbicoside|orbigenin 3-O-beta-D-xylopyranoside

orbicoside|orbigenin 3-O-beta-D-xylopyranoside

C35H60O11 (656.4135)


   

Grandidon D|grandidone D

Grandidon D|grandidone D

C40H48O8 (656.3349)


   

12-(2-Methylbutanoyl),7-ketone,1,11-di-Ac,Me ester-1,3,7,11,12-Pentahydroxy-14-meliacen-28-oic acid

12-(2-Methylbutanoyl),7-ketone,1,11-di-Ac,Me ester-1,3,7,11,12-Pentahydroxy-14-meliacen-28-oic acid

C36H48O11 (656.3196)


   

genkwanine G

genkwanine G

C37H52O10 (656.356)


   

xylorumphiin C

xylorumphiin C

C36H48O11 (656.3196)


   

12-O-cinnamoyl-3beta,8beta,12beta,14beta,17beta,20-hexahydroxy-(20S)-pregn-5-enyl-3-O-beta-D-cymaropyranoside|gymnepregoside I|penupogenin 3-O-beta-D-cymaropyranoside

12-O-cinnamoyl-3beta,8beta,12beta,14beta,17beta,20-hexahydroxy-(20S)-pregn-5-enyl-3-O-beta-D-cymaropyranoside|gymnepregoside I|penupogenin 3-O-beta-D-cymaropyranoside

C37H52O10 (656.356)


   

(6S,13S)-6-O-[4-O-acetyl-beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]cleroda-3,14-dien-13-ol

(6S,13S)-6-O-[4-O-acetyl-beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]cleroda-3,14-dien-13-ol

C34H56O12 (656.3772)


   

fibraurecdyside A

3-O-(beta-D-glucopyranosyl)-2beta,3beta,14alpha,20,22R,25-hexahydroxy-24R-methyl-5beta-cholest-7-en-6-one

C34H56O12 (656.3772)


   

12-(dodeca-2,4,6-trienoyl)-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one|EBI-59

12-(dodeca-2,4,6-trienoyl)-13-(2-methylbutanoyl)-6,7-epoxy-4,5,9,12,13,20-hexahydroxy-1-tigliaen-3-one|EBI-59

C37H52O10 (656.356)


   

3-O-Demethylmonensin

3-O-Demethylmonensin

C35H60O11 (656.4135)


   

(3beta,17alpha,20S)-pregn-5-ene-3,17,20-triol 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-digitalopyranoside|periseoside A

(3beta,17alpha,20S)-pregn-5-ene-3,17,20-triol 3-O-beta-D-glucopyranosyl-(1->4)-beta-D-digitalopyranoside|periseoside A

C34H56O12 (656.3772)


   

12-deacetyloxy-12-(2-methylbutanoyloxy)turrapubin A|turrapubin C

12-deacetyloxy-12-(2-methylbutanoyloxy)turrapubin A|turrapubin C

C36H48O11 (656.3196)


   

hypoglaside A

hypoglaside A

C36H48O11 (656.3196)


   

angustifonine A

angustifonine A

C41H44N4O4 (656.3362)


   

genkwadane C

genkwadane C

C37H52O10 (656.356)


   

bruceajavanone C

bruceajavanone C

C38H56O9 (656.3924)


   

cynanotoside C

cynanotoside C

C34H56O12 (656.3772)


   

6-O-[6-O-acetyl-beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]-(13E)-cleroda-3,13-dien-15-ol

6-O-[6-O-acetyl-beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]-(13E)-cleroda-3,13-dien-15-ol

C34H56O12 (656.3772)


   

PREGN-5-EN-20-ONE,3-[(6-O-B-D-GLUCOPYRANOSYL-B-D-GLUCOPYRANOSYL)OXY]-14-HYDROXY-,(3B,14B)- (9CI)

PREGN-5-EN-20-ONE,3-[(6-O-B-D-GLUCOPYRANOSYL-B-D-GLUCOPYRANOSYL)OXY]-14-HYDROXY-,(3B,14B)- (9CI)

C33H52O13 (656.3408)


   

3-O-alpha-L-rhamnopyranosyl-1-O-sulfo-(25S)-ruscogenin

3-O-alpha-L-rhamnopyranosyl-1-O-sulfo-(25S)-ruscogenin

C33H52O11S (656.323)


   

2alpha,3beta-dihydroxy-5alpha-pregn-16-en-20-one-3-O-beta-D-glucopyranosyl(1->4)-beta-D-galactopyranoside

2alpha,3beta-dihydroxy-5alpha-pregn-16-en-20-one-3-O-beta-D-glucopyranosyl(1->4)-beta-D-galactopyranoside

C33H52O13 (656.3408)


   

(6S,13S)-6-O-[6-O-acetyl-beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]cleroda-3,14-dien-13-ol

(6S,13S)-6-O-[6-O-acetyl-beta-D-glucopyranosyl-(1->4)-alpha-L-rhamnopyranosyl]cleroda-3,14-dien-13-ol

C34H56O12 (656.3772)


   

23xi,24xi-lanost-9(11)-en-3beta,7beta,16beta,19,23,24,25-heptaol 3-O-beta-D-xylopyranoside|orbicoside

23xi,24xi-lanost-9(11)-en-3beta,7beta,16beta,19,23,24,25-heptaol 3-O-beta-D-xylopyranoside|orbicoside

C35H60O11 (656.4135)


   

15G256gamma-OMe

15G256gamma-OMe

C34H48N4O9 (656.3421)


   

desacetylcinobufagin 3-succinyl-L-arginine ester

desacetylcinobufagin 3-succinyl-L-arginine ester

C34H48N4O9 (656.3421)


   

lycoclavanin tetraacetate|Lycoclavanin-tetraacetat

lycoclavanin tetraacetate|Lycoclavanin-tetraacetat

C38H56O9 (656.3924)


   

Arg Leu Leu Asn Asn

Arg Leu Leu Asn Asn

C28H52N10O8 (656.3969)


   

MLS000028713-01!DEFEROXAMINE MESYLATE

MLS000028713-01!DEFEROXAMINE MESYLATE

C26H52N6O11S (656.3415)


   

5,7-diacetoxy-3-benzoyloxy-14,15-dihydroxy-8-(2-methylbutyryloxy)-9-oxojatropha-6(17),11E-diene

5,7-diacetoxy-3-benzoyloxy-14,15-dihydroxy-8-(2-methylbutyryloxy)-9-oxojatropha-6(17),11E-diene

C36H48O11 (656.3196)


   

5,6,14-triacetoxy-3-benzoyloxy-8,15-dihydroxy-9-oxojatropha-6(17),11E-diene

5,6,14-triacetoxy-3-benzoyloxy-8,15-dihydroxy-9-oxojatropha-6(17),11E-diene

C36H48O11 (656.3196)


   

[1,3,12-triacetyloxy-17-(furan-3-yl)-4,4,8,10,13-pentamethyl-2,3,5,6,7,9,11,12,16,17-decahydro-1H-cyclopenta[a]phenanthren-7-yl] 2-hydroxy-3-methylbutanoate

NCGC00385570-01![1,3,12-triacetyloxy-17-(furan-3-yl)-4,4,8,10,13-pentamethyl-2,3,5,6,7,9,11,12,16,17-decahydro-1H-cyclopenta[a]phenanthren-7-yl] 2-hydroxy-3-methylbutanoate

C37H52O10 (656.356)


   

C33H52O13

NCGC00380159-01_C33H52O13_

C33H52O13 (656.3408)


   

DEFEROXAMINE MESYLATE_major

DEFEROXAMINE MESYLATE_major

C26H52N6O11S (656.3415)


   

Arg Arg Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N10O7 (656.3394)


   

Arg Tyr Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N10O7 (656.3394)


   

Arg Tyr Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C30H44N10O7 (656.3394)


   

Tyr Arg Arg Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanoic acid

C30H44N10O7 (656.3394)


   

Tyr Arg Tyr Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanoic acid

C30H44N10O7 (656.3394)


   

Tyr Tyr Arg Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-5-carbamimidamidopentanamido]-5-carbamimidamidopentanoic acid

C30H44N10O7 (656.3394)


   

PI(22:0/0:0)

1-docosanoyl-glycero-3-phospho-(1-myo-inositol)

C31H61O12P (656.39)


   

LPI 22:0

1-docosanoyl-glycero-3-phospho-(1-myo-inositol)

C31H61O12P (656.39)


   

Gyroxanthin

(3S,5R,6S,3S,5R,6R)-5,6-Epoxy-3-ethanoyloxy-7,8,6,7-tetradehydro-5,6,5,6-tetrahydro-beta,beta-carotene-3,19,5-triol

C42H56O6 (656.4077)


   

boc-ala-gly-pro-arg-7-amino-4-methylcoumarin

boc-ala-gly-pro-arg-7-amino-4-methylcoumarin

C31H44N8O8 (656.3282)


   

Deferoxamine mesylate

Deferoxamine (mesylate)

C26H52N6O11S (656.3415)


D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Deferoxamine mesylate (Deferoxamine B mesylate) is an iron chelator (binds to Fe(III) and many other metal cations), is widely used to reduce iron accumulation and deposition in tissues. Deferoxamine mesylate upregulates HIF-1α levels with good antioxidant activity. Deferoxamine mesylate also shows anti-proliferative activity, can induce apoptosis and autophagy in cancer cells. Deferoxamine mesylate can be used in studies of diabetes, neurodegenerative diseases as well as anti-cancer and anti-COVID-19[1][2][3][4][5].

   

(S)-Benzyl 2-((S)-4-methyl-2-((S)-2-(2-morpho lino acetamido)-4-phenylbutanamido)pentanamido)-3-phenylpropanoate

(S)-Benzyl 2-((S)-4-methyl-2-((S)-2-(2-morpho lino acetamido)-4-phenylbutanamido)pentanamido)-3-phenylpropanoate

C38H48N4O6 (656.3574)


   

Ac-tBu-Gly-tBu-Gly-Asn(Me)₂-Ala-AMC

Ac-tBu-Gly-tBu-Gly-Asn(Me)₂-Ala-AMC

C33H48N6O8 (656.3533)


   

(2E,4S,5S,6R,7R,8R,9R,10R,11S,12R,13Z,15E)-5,7,9,11-tetrahydroxy-17-[(6-hydroxy-3,7-dimethyl-1,4-dioxo-5,8-dihydronaphthalen-2-yl)amino]-2,4,6,8,10,12,16-heptamethyl-17-oxoheptadeca-2,13,15-trienoate

(2E,4S,5S,6R,7R,8R,9R,10R,11S,12R,13Z,15E)-5,7,9,11-tetrahydroxy-17-[(6-hydroxy-3,7-dimethyl-1,4-dioxo-5,8-dihydronaphthalen-2-yl)amino]-2,4,6,8,10,12,16-heptamethyl-17-oxoheptadeca-2,13,15-trienoate

C36H50NO10- (656.3435)


   

PA(12:0/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(12:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C35H61O9P (656.4053)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/12:0)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(12:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C35H61O9P (656.4053)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/12:0)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/12:0)

C35H61O9P (656.4053)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/12:0)

PA(20:3(5Z,11Z,14Z)-O(8,9)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:3(8Z,11Z,14Z)-O(5,6))

PA(12:0/20:3(8Z,11Z,14Z)-O(5,6))

C35H61O9P (656.4053)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/12:0)

PA(20:3(8Z,11Z,14Z)-O(5,6)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(12:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C35H61O9P (656.4053)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/12:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(12:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/12:0)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(12:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/12:0)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(12:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C35H61O9P (656.4053)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/12:0)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/12:0)

C35H61O9P (656.4053)


   

PA(12:0/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(12:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C35H61O9P (656.4053)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/12:0)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/12:0)

C35H61O9P (656.4053)


   

PA(14:1(9Z)/18:2(10E,12Z)+=O(9))

PA(14:1(9Z)/18:2(10E,12Z)+=O(9))

C35H61O9P (656.4053)


   

PA(18:2(10E,12Z)+=O(9)/14:1(9Z))

PA(18:2(10E,12Z)+=O(9)/14:1(9Z))

C35H61O9P (656.4053)


   

PA(14:1(9Z)/18:2(9Z,11E)+=O(13))

PA(14:1(9Z)/18:2(9Z,11E)+=O(13))

C35H61O9P (656.4053)


   

PA(18:2(9Z,11E)+=O(13)/14:1(9Z))

PA(18:2(9Z,11E)+=O(13)/14:1(9Z))

C35H61O9P (656.4053)


   

PA(i-12:0/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(i-12:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C35H61O9P (656.4053)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/i-12:0)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(i-12:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C35H61O9P (656.4053)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/i-12:0)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:3(5Z,11Z,14Z)-O(8,9))

PA(i-12:0/20:3(5Z,11Z,14Z)-O(8,9))

C35H61O9P (656.4053)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/i-12:0)

PA(20:3(5Z,11Z,14Z)-O(8,9)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:3(8Z,11Z,14Z)-O(5,6))

PA(i-12:0/20:3(8Z,11Z,14Z)-O(5,6))

C35H61O9P (656.4053)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/i-12:0)

PA(20:3(8Z,11Z,14Z)-O(5,6)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/i-12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(i-12:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C35H61O9P (656.4053)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/i-12:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/i-12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/i-12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/i-12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(i-12:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/i-12:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(i-12:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/i-12:0)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(i-12:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C35H61O9P (656.4053)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/i-12:0)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(i-12:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C35H61O9P (656.4053)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/i-12:0)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/i-12:0)

C35H61O9P (656.4053)


   

PA(i-12:0/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(i-12:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C35H61O9P (656.4053)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/i-12:0)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/i-12:0)

C35H61O9P (656.4053)


   

PA(14:1(9Z)/18:3(10,12,15)-OH(9))

PA(14:1(9Z)/18:3(10,12,15)-OH(9))

C35H61O9P (656.4053)


   

PA(18:3(10,12,15)-OH(9)/14:1(9Z))

PA(18:3(10,12,15)-OH(9)/14:1(9Z))

C35H61O9P (656.4053)


   

PA(14:1(9Z)/18:3(9,11,15)-OH(13))

PA(14:1(9Z)/18:3(9,11,15)-OH(13))

C35H61O9P (656.4053)


   

PA(18:3(9,11,15)-OH(13)/14:1(9Z))

PA(18:3(9,11,15)-OH(13)/14:1(9Z))

C35H61O9P (656.4053)


   

N-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide methanesulfonate

N-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide methanesulfonate

C26H52N6O11S (656.3415)


D064449 - Sequestering Agents > D002614 - Chelating Agents > D007502 - Iron Chelating Agents

   

1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(1-naphthalenyl)urea

1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenylphenyl)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-3-(1-naphthalenyl)urea

C41H44N4O4 (656.3362)


   

N-[(3R,9S,10S)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

N-[(3R,9S,10S)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

C33H51F3N4O6 (656.3761)


   

N-[(3R,9R,10R)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

N-[(3R,9R,10R)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

C33H51F3N4O6 (656.3761)


   

N-[(3R,9S,10S)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

N-[(3R,9S,10S)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

C33H51F3N4O6 (656.3761)


   

N-[(3R,9S,10R)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

N-[(3R,9S,10R)-9-[[[(cyclohexylamino)-oxomethyl]-methylamino]methyl]-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4,4,4-trifluorobutanamide

C33H51F3N4O6 (656.3761)


   

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] docosanoate

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] docosanoate

C31H61O12P (656.39)


   

Smgdg O-13:0_9:0

Smgdg O-13:0_9:0

C31H60O12S (656.3805)


   

Smgdg O-14:0_8:0

Smgdg O-14:0_8:0

C31H60O12S (656.3805)


   

Smgdg O-17:0_5:0

Smgdg O-17:0_5:0

C31H60O12S (656.3805)


   

Smgdg O-19:0_3:0

Smgdg O-19:0_3:0

C31H60O12S (656.3805)


   

Smgdg O-9:0_13:0

Smgdg O-9:0_13:0

C31H60O12S (656.3805)


   

Smgdg O-15:0_7:0

Smgdg O-15:0_7:0

C31H60O12S (656.3805)


   

Smgdg O-16:0_6:0

Smgdg O-16:0_6:0

C31H60O12S (656.3805)


   

Smgdg O-8:0_14:0

Smgdg O-8:0_14:0

C31H60O12S (656.3805)


   

Smgdg O-18:0_4:0

Smgdg O-18:0_4:0

C31H60O12S (656.3805)


   

Smgdg O-20:0_2:0

Smgdg O-20:0_2:0

C31H60O12S (656.3805)


   

Smgdg O-12:0_10:0

Smgdg O-12:0_10:0

C31H60O12S (656.3805)


   

Smgdg O-11:0_11:0

Smgdg O-11:0_11:0

C31H60O12S (656.3805)


   

Smgdg O-10:0_12:0

Smgdg O-10:0_12:0

C31H60O12S (656.3805)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate

C35H61O9P (656.4053)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] undecanoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] undecanoate

C35H61O9P (656.4053)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C35H61O9P (656.4053)


   

[1-Dodecoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

[1-Dodecoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] decanoate

C31H61O12P (656.39)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (Z)-tridec-9-enoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (Z)-tridec-9-enoate

C35H61O9P (656.4053)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecoxypropan-2-yl] undecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-undecoxypropan-2-yl] undecanoate

C31H61O12P (656.39)


   

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] dodecanoate

[1-Decoxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] dodecanoate

C31H61O12P (656.39)


   
   

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

[1-[(2-hexanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C34H57O10P (656.3689)


   

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-octanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C34H57O10P (656.3689)


   

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-[(2-decanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C34H57O10P (656.3689)


   

[1-Hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] pentadecanoate

[1-Hexanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] pentadecanoate

C30H57O13P (656.3537)


   

[1-Heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] tetradecanoate

[1-Heptanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] tetradecanoate

C30H57O13P (656.3537)


   

[1-Butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] heptadecanoate

[1-Butanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] heptadecanoate

C30H57O13P (656.3537)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-octanoyloxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate

C34H57O10P (656.3689)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] dodecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-nonanoyloxypropan-2-yl] dodecanoate

C30H57O13P (656.3537)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] tridecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-octanoyloxypropan-2-yl] tridecanoate

C30H57O13P (656.3537)


   

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexanoyloxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C34H57O10P (656.3689)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] octadecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-propanoyloxypropan-2-yl] octadecanoate

C30H57O13P (656.3537)


   

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] hexadecanoate

[1-[Hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxy-3-pentanoyloxypropan-2-yl] hexadecanoate

C30H57O13P (656.3537)


   

[1-Decanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] undecanoate

[1-Decanoyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] undecanoate

C30H57O13P (656.3537)


   

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

[1-decanoyloxy-3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C34H57O10P (656.3689)


   

[1,3,12-triacetyloxy-17-(furan-3-yl)-4,4,8,10,13-pentamethyl-2,3,5,6,7,9,11,12,16,17-decahydro-1H-cyclopenta[a]phenanthren-7-yl] 2-hydroxy-3-methylbutanoate

[1,3,12-triacetyloxy-17-(furan-3-yl)-4,4,8,10,13-pentamethyl-2,3,5,6,7,9,11,12,16,17-decahydro-1H-cyclopenta[a]phenanthren-7-yl] 2-hydroxy-3-methylbutanoate

C37H52O10 (656.356)


   

[1-Acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] nonadecanoate

[1-Acetyloxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropan-2-yl] nonadecanoate

C30H57O13P (656.3537)


   

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoate

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoate

C37H53O8P (656.3478)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoate

C34H57O10P (656.3689)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxypropan-2-yl] (4E,7E)-hexadeca-4,7-dienoate

C34H57O10P (656.3689)


   

[(2R)-2-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] undecanoate

[(2R)-2-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropyl] undecanoate

C30H57O13P (656.3537)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(6E,9E)-dodeca-6,9-dienoyl]oxypropan-2-yl] (9E,11E,13E)-hexadeca-9,11,13-trienoate

C34H57O10P (656.3689)


   

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-dodec-5-enoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

[1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-dodec-5-enoyl]oxypropan-2-yl] (7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoate

C34H57O10P (656.3689)


   

[(2R)-1-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] undecanoate

[(2R)-1-decanoyloxy-3-[hydroxy-[(5R)-2,3,4,5,6-pentahydroxycyclohexyl]oxyphosphoryl]oxypropan-2-yl] undecanoate

C30H57O13P (656.3537)


   

N3-Acetylneomycin

N3-Acetylneomycin

C25H48N6O14 (656.3228)


   

1-docosanoyl-glycero-3-phospho-(1-myo-inositol)

1-docosanoyl-glycero-3-phospho-(1-myo-inositol)

C31H61O12P (656.39)


   
   
   
   
   
   
   
   

PA P-20:1/12:3;O2

PA P-20:1/12:3;O2

C35H61O9P (656.4053)


   

PA 14:1/18:3;O

PA 14:1/18:3;O

C35H61O9P (656.4053)


   

PA 18:1/13:4;O2

PA 18:1/13:4;O2

C34H57O10P (656.3689)


   

PA 18:2/13:3;O2

PA 18:2/13:3;O2

C34H57O10P (656.3689)


   

PA 18:3/12:3;O3

PA 18:3/12:3;O3

C33H53O11P (656.3325)


   

PA 18:4/12:2;O3

PA 18:4/12:2;O3

C33H53O11P (656.3325)


   

PA 20:1/12:3;O

PA 20:1/12:3;O

C35H61O9P (656.4053)


   
   
   
   
   
   
   

PG O-11:0/18:5

PG O-11:0/18:5

C35H61O9P (656.4053)


   
   

PG P-18:1/9:5;O2

PG P-18:1/9:5;O2

C33H53O11P (656.3325)


   
   
   
   
   
   
   

PI O-16:0/5:1;O

PI O-16:0/5:1;O

C30H57O13P (656.3537)


   

PI O-18:0/4:0

PI O-18:0/4:0

C31H61O12P (656.39)


   

PI O-20:0/2:0

PI O-20:0/2:0

C31H61O12P (656.39)


   
   
   
   
   
   
   
   
   

ST 27:2;O7;GlcA

ST 27:2;O7;GlcA

C33H52O13 (656.3408)


   

ST 28:1;O6;GlcA

ST 28:1;O6;GlcA

C34H56O12 (656.3772)


   

ST 29:0;O5;GlcA

ST 29:0;O5;GlcA

C35H60O11 (656.4135)


   

ST 27:3;O8;Hex

ST 27:3;O8;Hex

C33H52O13 (656.3408)


   

ST 29:1;O6;Hex

ST 29:1;O6;Hex

C35H60O11 (656.4135)


   
   

(1s,3as,5ar,7r,8s,9ar,9br,11ar)-3a,8-dihydroxy-9a,11a-dimethyl-1-[(2s,3r,5r)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,3as,5ar,7r,8s,9ar,9br,11ar)-3a,8-dihydroxy-9a,11a-dimethyl-1-[(2s,3r,5r)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C34H56O12 (656.3772)


   

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18r)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18r)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

C36H52N2O9 (656.3673)


   

methyl (1r,2s,5s)-16-[(2z,6e)-3-[(acetyloxy)methyl]-7,11-dimethyldodeca-2,6,10-trien-1-yl]-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

methyl (1r,2s,5s)-16-[(2z,6e)-3-[(acetyloxy)methyl]-7,11-dimethyldodeca-2,6,10-trien-1-yl]-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C40H48O8 (656.3349)


   

[5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl dec-2-enoate

[5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl dec-2-enoate

C37H52O10 (656.356)


   

n-{1-[8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl}-4-methyl-2-(methylamino)pentanimidic acid

n-{1-[8,11-dihydroxy-10-(sec-butyl)-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl}-4-methyl-2-(methylamino)pentanimidic acid

C37H48N6O5 (656.3686)


   

methyl 16-{3-[(acetyloxy)methyl]-7,11-dimethyldodeca-2,6,10-trien-1-yl}-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

methyl 16-{3-[(acetyloxy)methyl]-7,11-dimethyldodeca-2,6,10-trien-1-yl}-10,14-dihydroxy-2-(prop-1-en-2-yl)-6,18-dioxapentacyclo[9.7.1.1¹,⁵.0⁷,¹⁹.0¹²,¹⁷]icosa-7(19),8,10,12,14,16-hexaene-5-carboxylate

C40H48O8 (656.3349)


   

(2s,3r,4s,5r)-2-{[(1r,2s,3as,3bs,4s,5ar,7s,9ar,11ar)-2,4-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-[(2r,4s,5s)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5r)-2-{[(1r,2s,3as,3bs,4s,5ar,7s,9ar,11ar)-2,4-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-[(2r,4s,5s)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

C35H60O11 (656.4135)


   

[(1r,2r,3r,4s,5r,6s,8r,9r,10r,16s,18r)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

[(1r,2r,3r,4s,5r,6s,8r,9r,10r,16s,18r)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

C36H52N2O9 (656.3673)


   

n-[2-({[(1s,2r,3r,4s,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[(1s,2r,3r,4s,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C35H48N2O10 (656.3309)


   

{6-[(4,5-dihydroxy-6-{[4-(3-hydroxy-3-methylpent-4-en-1-yl)-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-2-methyloxan-3-yl)oxy]-3,4,5-trihydroxyoxan-2-yl}methyl acetate

{6-[(4,5-dihydroxy-6-{[4-(3-hydroxy-3-methylpent-4-en-1-yl)-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-2-methyloxan-3-yl)oxy]-3,4,5-trihydroxyoxan-2-yl}methyl acetate

C34H56O12 (656.3772)


   

1,4,7,10,13-pentahydroxy-15-[(4-hydroxyphenyl)methyl]-9-isopropyl-12-(3-methylbutan-2-yl)-6-(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

1,4,7,10,13-pentahydroxy-15-[(4-hydroxyphenyl)methyl]-9-isopropyl-12-(3-methylbutan-2-yl)-6-(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C34H52N6O7 (656.3897)


   

4-(acetyloxy)-1-[5-(3,3-dimethyloxiran-2-yl)-2-methoxyoxolan-3-yl]-9-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl 2-methylbut-2-enoate

4-(acetyloxy)-1-[5-(3,3-dimethyloxiran-2-yl)-2-methoxyoxolan-3-yl]-9-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl 2-methylbut-2-enoate

C38H56O9 (656.3924)


   

[(1r,2r,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18r)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

[(1r,2r,3r,4s,5r,6s,8r,9r,10r,13s,16s,17r,18r)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

C36H52N2O9 (656.3673)


   

17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl 2-methylbut-2-enoate

C36H48O11 (656.3196)


   

(1r,2r,4s,5s,6s,10r,11s,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-3,4-dimethylpent-2-enoate

(1r,2r,4s,5s,6s,10r,11s,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-3,4-dimethylpent-2-enoate

C37H52O10 (656.356)


   

(2's,4as,7's,9s,10as)-6,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,8,8',10,14'-pentone

(2's,4as,7's,9s,10as)-6,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,8,8',10,14'-pentone

C40H48O8 (656.3349)


   

2-[(6-{[3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

2-[(6-{[3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,13s,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e)-dec-2-enoate

[(1r,2r,4s,5s,6r,7s,8r,9s,10s,11r,13s,15r,17r)-5,6,7,8,9-pentahydroxy-4,17-dimethyl-13-phenyl-15-(prop-1-en-2-yl)-12,14,18-trioxapentacyclo[11.4.1.0¹,¹⁰.0²,⁶.0¹¹,¹⁵]octadecan-8-yl]methyl (2e)-dec-2-enoate

C37H52O10 (656.356)


   

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-{[(2s)-2-methylbutanoyl]oxy}-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methyl 2-aminobenzoate

C36H52N2O9 (656.3673)


   

1-(7-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)ethanone

1-(7-{[3,4-dihydroxy-6-(hydroxymethyl)-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl)ethanone

C33H52O13 (656.3408)


   

(6r,9s,12s,15s,20as)-1,4,7,10,13-pentahydroxy-15-[(4-hydroxyphenyl)methyl]-9-isopropyl-12-[(2r)-3-methylbutan-2-yl]-6-(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

(6r,9s,12s,15s,20as)-1,4,7,10,13-pentahydroxy-15-[(4-hydroxyphenyl)methyl]-9-isopropyl-12-[(2r)-3-methylbutan-2-yl]-6-(2-methylpropyl)-3h,6h,9h,12h,15h,18h,19h,20h,20ah-pyrrolo[1,2-a]1,4,7,10,13,16-hexaazacyclooctadecan-16-one

C34H52N6O7 (656.3897)


   

6,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,8,8',10,14'-pentone

6,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,8,8',10,14'-pentone

C40H48O8 (656.3349)


   

(1s,2s,4r,8r,9r,10z,12r)-11-({[(2s,3s,4s,5s)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate

(1s,2s,4r,8r,9r,10z,12r)-11-({[(2s,3s,4s,5s)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate

C35H48N2O10 (656.3309)


   

3a,8-dihydroxy-9a,11a-dimethyl-1-(2,3,6-trihydroxy-5,6-dimethylheptan-2-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

3a,8-dihydroxy-9a,11a-dimethyl-1-(2,3,6-trihydroxy-5,6-dimethylheptan-2-yl)-7-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C34H56O12 (656.3772)


   

{11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-[(2-methylbutanoyl)oxy]-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-aminobenzoate

{11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-4-[(2-methylbutanoyl)oxy]-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl}methyl 2-aminobenzoate

C36H52N2O9 (656.3673)


   

4-(2-{2-ethyl-5'-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl)-3-methoxypentanoic acid

4-(2-{2-ethyl-5'-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl)-3-methoxypentanoic acid

C35H60O11 (656.4135)


   

(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-[(3s)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-[(3s)-2-oxo-3h-furan-3-yl]-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C36H48O11 (656.3196)


   

[(1r,2r,4r,5r,6s,7s,8r,9s,10r,11s,12s,13s,14r,24r)-7,8,9,10,11-pentahydroxy-2,12,14-trimethyl-4-(prop-1-en-2-yl)-23,25,26-trioxahexacyclo[11.10.1.1⁴,²².1⁵,²².0¹,⁶.0¹⁰,²⁴]hexacosan-8-yl]methyl benzoate

[(1r,2r,4r,5r,6s,7s,8r,9s,10r,11s,12s,13s,14r,24r)-7,8,9,10,11-pentahydroxy-2,12,14-trimethyl-4-(prop-1-en-2-yl)-23,25,26-trioxahexacyclo[11.10.1.1⁴,²².1⁵,²².0¹,⁶.0¹⁰,²⁴]hexacosan-8-yl]methyl benzoate

C37H52O10 (656.356)


   

(3s,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2s,2'r,3's,5r,5'r)-2-ethyl-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl]-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxypentanoic acid

(3s,4s)-4-[(2s,5r,7s,8r,9s)-2-[(2s,2'r,3's,5r,5'r)-2-ethyl-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl]-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxypentanoic acid

C35H60O11 (656.4135)


   

5-[(3-{6-[1-(5,5-dimethyl-4-oxofuran-2-yl)ethenyl]-2-hydroxy-5,6-dihydro-2h-pyran-3-yl}-3a,6,6,9a-tetramethyl-2,7-dioxo-octahydrocyclopenta[a]naphthalen-8-yl)oxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

5-[(3-{6-[1-(5,5-dimethyl-4-oxofuran-2-yl)ethenyl]-2-hydroxy-5,6-dihydro-2h-pyran-3-yl}-3a,6,6,9a-tetramethyl-2,7-dioxo-octahydrocyclopenta[a]naphthalen-8-yl)oxy]-3-hydroxy-3-methyl-5-oxopentanoic acid

C36H48O11 (656.3196)


   

[(1r,3s,3ar,5as,5bs,6s,7ar,10r,11as,13ar,13br)-1,6,10-tris(acetyloxy)-3-isopropyl-5a,8,8,11a,13a-pentamethyl-9-oxo-1h,2h,3h,4h,5h,5bh,6h,7h,7ah,10h,11h,13h,13bh-cyclopenta[a]chrysen-3a-yl]methyl acetate

[(1r,3s,3ar,5as,5bs,6s,7ar,10r,11as,13ar,13br)-1,6,10-tris(acetyloxy)-3-isopropyl-5a,8,8,11a,13a-pentamethyl-9-oxo-1h,2h,3h,4h,5h,5bh,6h,7h,7ah,10h,11h,13h,13bh-cyclopenta[a]chrysen-3a-yl]methyl acetate

C38H56O9 (656.3924)


   

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4r,4ar,8ar)-4-[(3e)-5-hydroxy-3-methylpent-3-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4r,4ar,8ar)-4-[(3e)-5-hydroxy-3-methylpent-3-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C34H56O12 (656.3772)


   

(2r,4s,5s)-2-{[(3s,4r,6r)-6-{[(1s,3as,7s,9ar,11ar)-3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,4s,5s)-2-{[(3s,4r,6r)-6-{[(1s,3as,7s,9ar,11ar)-3a-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

(2's,4as,7's,9r,10as)-6,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,8,8',10,14'-pentone

(2's,4as,7's,9r,10as)-6,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,8,8',10,14'-pentone

C40H48O8 (656.3349)


   

(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-16-(prop-1-en-2-yl)-14-[(1e,3e)-tetradeca-1,3-dien-1-yl]-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate

(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18r)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-16-(prop-1-en-2-yl)-14-[(1e,3e)-tetradeca-1,3-dien-1-yl]-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate

C37H52O10 (656.356)


   

6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-18-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl 2-methylbutanoate

6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-18-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl 2-methylbutanoate

C36H48O11 (656.3196)


   

8-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-2-[6-(3-hydroxypentan-2-yl)-3,5-dimethyl-4-oxopyran-2-yl]-4,6-dimethyl-5-(propanoyloxy)non-6-en-3-yl propanoate

8-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-2-[6-(3-hydroxypentan-2-yl)-3,5-dimethyl-4-oxopyran-2-yl]-4,6-dimethyl-5-(propanoyloxy)non-6-en-3-yl propanoate

C38H56O9 (656.3924)


   

methyl 3-[(3s,6r,9r,12s,13s)-13-[(2r)-decan-2-yl]-5,8,11-trihydroxy-3-(hydroxymethyl)-6-(1h-indole-3-carbonyl)-12-methyl-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-9-yl]propanoate

methyl 3-[(3s,6r,9r,12s,13s)-13-[(2r)-decan-2-yl]-5,8,11-trihydroxy-3-(hydroxymethyl)-6-(1h-indole-3-carbonyl)-12-methyl-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-9-yl]propanoate

C34H48N4O9 (656.3421)


   

(3s,4s)-4-[(2s,7s,8r,9s)-2-[(2s,2'r,3's,5r,5'r)-2-ethyl-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl]-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxypentanoic acid

(3s,4s)-4-[(2s,7s,8r,9s)-2-[(2s,2'r,3's,5r,5'r)-2-ethyl-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-3'-methyl-[2,2'-bioxolan]-5-yl]-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxypentanoic acid

C35H60O11 (656.4135)


   

(2e,6r)-6-[(1r,3ar,5ar,6r,9as,11ar)-6-({[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}methyl)-3a,6,9a,11a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

(2e,6r)-6-[(1r,3ar,5ar,6r,9as,11ar)-6-({[(3s)-4-carboxy-3-hydroxy-3-methylbutanoyl]oxy}methyl)-3a,6,9a,11a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-2-methylhept-2-enoic acid

C36H48O11 (656.3196)


   

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C35H48N2O10 (656.3309)


   

(2s,3e,5r,6s,7s,8s)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2r,3r)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethyl-7-(propanoyloxy)non-3-en-5-yl propanoate

(2s,3e,5r,6s,7s,8s)-2-(6-ethyl-3,5-dimethyl-4-oxopyran-2-yl)-8-{6-[(2r,3r)-3-hydroxypentan-2-yl]-3,5-dimethyl-4-oxopyran-2-yl}-4,6-dimethyl-7-(propanoyloxy)non-3-en-5-yl propanoate

C38H56O9 (656.3924)


   

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4r,4ar,8ar)-4-[(3s)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4r,4ar,8ar)-4-[(3s)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C34H56O12 (656.3772)


   

(1s,2s,4r,8r,9s,10z,12r)-11-({[(2r,3s,4r,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2z)-3-(1-methylimidazol-4-yl)prop-2-enoate

(1s,2s,4r,8r,9s,10z,12r)-11-({[(2r,3s,4r,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2z)-3-(1-methylimidazol-4-yl)prop-2-enoate

C35H48N2O10 (656.3309)


   

2-{[2,5-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-(4,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

2-{[2,5-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-(4,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

C35H60O11 (656.4135)


   

(2s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-4-methyl-2-(methylamino)pentanimidic acid

(2s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-4-methyl-2-(methylamino)pentanimidic acid

C37H48N6O5 (656.3686)


   

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3r)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-3,4-dimethylpent-2-enoate

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3r)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-3,4-dimethylpent-2-enoate

C37H52O10 (656.356)


   

{6-[(4,5-dihydroxy-6-{[4-(5-hydroxy-3-methylpent-3-en-1-yl)-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-2-methyloxan-3-yl)oxy]-3,4,5-trihydroxyoxan-2-yl}methyl acetate

{6-[(4,5-dihydroxy-6-{[4-(5-hydroxy-3-methylpent-3-en-1-yl)-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-2-methyloxan-3-yl)oxy]-3,4,5-trihydroxyoxan-2-yl}methyl acetate

C34H56O12 (656.3772)


   

(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-9-hydroxy-2-[(2s,2'r,3's,5r,5'r)-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-2,3'-dimethyl-[2,2'-bioxolan]-5-yl]-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxy-2-methylpentanoic acid

(2s,3r,4s)-4-[(2s,5r,7s,8r,9s)-9-hydroxy-2-[(2s,2'r,3's,5r,5'r)-5'-[(2s,3s,5r,6r)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-2,3'-dimethyl-[2,2'-bioxolan]-5-yl]-2,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl]-3-methoxy-2-methylpentanoic acid

C35H60O11 (656.4135)


   

5-{[(3r,3ar,5ar,8r,9ar,9br)-3-[(2r,6s)-6-[1-(5,5-dimethyl-4-oxofuran-2-yl)ethenyl]-2-hydroxy-5,6-dihydro-2h-pyran-3-yl]-3a,6,6,9a-tetramethyl-2,7-dioxo-octahydrocyclopenta[a]naphthalen-8-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

5-{[(3r,3ar,5ar,8r,9ar,9br)-3-[(2r,6s)-6-[1-(5,5-dimethyl-4-oxofuran-2-yl)ethenyl]-2-hydroxy-5,6-dihydro-2h-pyran-3-yl]-3a,6,6,9a-tetramethyl-2,7-dioxo-octahydrocyclopenta[a]naphthalen-8-yl]oxy}-3-hydroxy-3-methyl-5-oxopentanoic acid

C36H48O11 (656.3196)


   

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8r,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C36H48O11 (656.3196)


   

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4s,4ar,8ar)-4-[(3e)-5-hydroxy-3-methylpent-3-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4s,4ar,8ar)-4-[(3e)-5-hydroxy-3-methylpent-3-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C34H56O12 (656.3772)


   

(1s,3br,4r,5ar,9s,9as,9br,10r,11as)-4-(acetyloxy)-1-[(2r,3s,5s)-5-[(2s)-3,3-dimethyloxiran-2-yl]-2-methoxyoxolan-3-yl]-9-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl (2e)-2-methylbut-2-enoate

(1s,3br,4r,5ar,9s,9as,9br,10r,11as)-4-(acetyloxy)-1-[(2r,3s,5s)-5-[(2s)-3,3-dimethyloxiran-2-yl]-2-methoxyoxolan-3-yl]-9-hydroxy-3b,6,6,9a,11a-pentamethyl-7-oxo-1h,2h,4h,5h,5ah,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-10-yl (2e)-2-methylbut-2-enoate

C38H56O9 (656.3924)


   

1-[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-9a,11a-dimethyl-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C33H52O13 (656.3408)


   

(1r,6r,7r,10r,11s,12s,14r,15r,16s,18r)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-18-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl (2s)-2-methylbutanoate

(1r,6r,7r,10r,11s,12s,14r,15r,16s,18r)-6-(furan-3-yl)-16-hydroxy-12-(2-methoxy-2-oxoethyl)-7,11,13,13-tetramethyl-18-[(2-methylpropanoyl)oxy]-4-oxo-5,17-dioxapentacyclo[13.2.1.0¹,¹⁰.0²,⁷.0¹¹,¹⁶]octadec-2-en-14-yl (2s)-2-methylbutanoate

C36H48O11 (656.3196)


   

(2s,3r,4s,5r,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-1-[(1r)-1-hydroxyethyl]-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5r,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-1-[(1r)-1-hydroxyethyl]-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

(2r,3s,5s)-2-{1-[(1s,3as,7s,9ar,11ar)-7-{[(2r,3s,5s)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3s,5s)-2-{1-[(1s,3as,7s,9ar,11ar)-7-{[(2r,3s,5s)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

6-(6-{[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]methyl}-3a,6,9a,11a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-2-methylhept-2-enoic acid

6-(6-{[(4-carboxy-3-hydroxy-3-methylbutanoyl)oxy]methyl}-3a,6,9a,11a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl)-2-methylhept-2-enoic acid

C36H48O11 (656.3196)


   

(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18s)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-16-(prop-1-en-2-yl)-14-[(1e,3e)-tetradeca-1,3-dien-1-yl]-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate

(1r,2r,6s,7s,8r,10s,11s,12r,14s,16s,17r,18s)-6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-16-(prop-1-en-2-yl)-14-[(1e,3e)-tetradeca-1,3-dien-1-yl]-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate

C37H52O10 (656.356)


   

6-[(4,5-dihydroxy-6-{[4-(3-hydroxy-3-methylpent-4-en-1-yl)-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-2-methyloxan-3-yl)oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl acetate

6-[(4,5-dihydroxy-6-{[4-(3-hydroxy-3-methylpent-4-en-1-yl)-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-2-methyloxan-3-yl)oxy]-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl acetate

C34H56O12 (656.3772)


   

(2'r,4as,7'r,9r,10as)-8,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,6,8',10,14'-pentone

(2'r,4as,7'r,9r,10as)-8,15'-dihydroxy-7,13'-diisopropyl-1,1,2',4a,6',6'-hexamethyl-2,3,4,10a-tetrahydro-11'-oxaspiro[phenanthrene-9,10'-tetracyclo[7.6.1.0²,⁷.0¹²,¹⁶]hexadecane]-1'(15'),9'(16'),12'-triene-5,6,8',10,14'-pentone

C40H48O8 (656.3349)


   

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

(1r,2r,4r,6s,8s,11r,12s,13r,16r,17r,19s,20r)-17,19-bis(acetyloxy)-4-methoxy-1,9,11,16-tetramethyl-8-(2-oxo-5h-furan-3-yl)-5,14-dioxapentacyclo[11.6.1.0²,¹¹.0⁶,¹⁰.0¹⁶,²⁰]icos-9-en-12-yl (2e)-2-methylbut-2-enoate

C36H48O11 (656.3196)


   

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4s,4ar,8ar)-4-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

[(2r,3s,4s,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4s,4ar,8ar)-4-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-3,4,5-trihydroxyoxan-2-yl]methyl acetate

C34H56O12 (656.3772)


   

(2r,3s,4r,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4r,4ar,8ar)-4-[(3s)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl acetate

(2r,3s,4r,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4r,4ar,8ar)-4-[(3s)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl acetate

C34H56O12 (656.3772)


   

(1s,2s,4r,8r,9r,10z,12r)-11-({[(2s,3s,4r,5s)-4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate

(1s,2s,4r,8r,9r,10z,12r)-11-({[(2s,3s,4r,5s)-4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate

C35H48N2O10 (656.3309)


   

(1s,2s,4r,8r,9r,10z,12r)-11-({[(2r,3r,4s,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2z)-3-(1-methylimidazol-4-yl)prop-2-enoate

(1s,2s,4r,8r,9r,10z,12r)-11-({[(2r,3r,4s,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2z)-3-(1-methylimidazol-4-yl)prop-2-enoate

C35H48N2O10 (656.3309)


   

(1's,2r,2's,4s,4's,5s,7's,8'r,9's,12's,13'r,15'r,16'r,18's)-4,15',16',18'-tetrahydroxy-5,7',9',13'-tetramethyl-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-19'-one

(1's,2r,2's,4s,4's,5s,7's,8'r,9's,12's,13'r,15'r,16'r,18's)-4,15',16',18'-tetrahydroxy-5,7',9',13'-tetramethyl-4-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosan]-19'-one

C33H52O13 (656.3408)


   

(2r,3r,4s,5r,6r)-2-[(1s)-1-[(1s,3as,3br,7s,9ar,9bs,11ar)-7-{[(2r,3r,4s,5s,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5r,6r)-2-[(1s)-1-[(1s,3as,3br,7s,9ar,9bs,11ar)-7-{[(2r,3r,4s,5s,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

(2r,3r,4s,5s,6r)-2-{1-[(1s,3as,3br,7s,9ar,9bs,11ar)-7-{[(2r,3r,4s,5s,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2r,3r,4s,5s,6r)-2-{1-[(1s,3as,3br,7s,9ar,9bs,11ar)-7-{[(2r,3r,4s,5s,6r)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy}-3a-hydroxy-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1r,3as,3br,7s,9ar,9bs,11as)-1-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1r,3as,3br,7s,9ar,9bs,11as)-1-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-16-(prop-1-en-2-yl)-14-(tetradeca-1,3-dien-1-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate

6,7-dihydroxy-8-(hydroxymethyl)-4,18-dimethyl-5-oxo-16-(prop-1-en-2-yl)-14-(tetradeca-1,3-dien-1-yl)-9,13,15,19-tetraoxahexacyclo[12.4.1.0¹,¹¹.0²,⁶.0⁸,¹⁰.0¹²,¹⁶]nonadec-3-en-17-yl acetate

C37H52O10 (656.356)


   

(2s,3s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-3-methyl-2-(methylamino)pentanimidic acid

(2s,3s)-n-[(2s)-1-[(3s,7s,10s,13z)-10-[(2s)-butan-2-yl]-8,11-dihydroxy-2-oxa-6,9,12-triazatricyclo[13.2.2.0³,⁷]nonadeca-1(17),8,11,13,15,18-hexaen-6-yl]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]-3-methyl-2-(methylamino)pentanimidic acid

C37H48N6O5 (656.3686)


   

2-{[2,4-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-(4,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

2-{[2,4-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-(4,5,6-trihydroxy-6-methylheptan-2-yl)-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

C35H60O11 (656.4135)


   

5-carbamimidamido-2-[(1-hydroxy-4-{[5-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-4-oxobutylidene)amino]pentanoic acid

5-carbamimidamido-2-[(1-hydroxy-4-{[5-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-4-oxobutylidene)amino]pentanoic acid

C34H48N4O9 (656.3421)


   

n-[2-({[4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C35H48N2O10 (656.3309)


   

1-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5r,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone

1-[(1s,3as,3br,5as,7s,9as,9bs,11ar)-3a-hydroxy-7-{[(2r,3r,4r,5r,6r)-3-hydroxy-4-methoxy-6-methyl-5-{[(2s,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-tetradecahydrocyclopenta[a]phenanthren-1-yl]ethanone

C34H56O12 (656.3772)


   

(2s,3r,4s,5r)-2-{[(1r,2s,3as,3bs,5s,5ar,7s,9ar,11ar)-2,5-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-[(2r,4s,5s)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

(2s,3r,4s,5r)-2-{[(1r,2s,3as,3bs,5s,5ar,7s,9ar,11ar)-2,5-dihydroxy-9a-(hydroxymethyl)-3a,6,6,11a-tetramethyl-1-[(2r,4s,5s)-4,5,6-trihydroxy-6-methylheptan-2-yl]-1h,2h,3h,3bh,4h,5h,5ah,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxane-3,4,5-triol

C35H60O11 (656.4135)


   

11-({[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl 3-(1-methylimidazol-4-yl)prop-2-enoate

11-({[3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl 3-(1-methylimidazol-4-yl)prop-2-enoate

C35H48N2O10 (656.3309)


   

(1s,3as,5ar,7r,8s,9ar,9br,11ar)-3a,8-dihydroxy-9a,11a-dimethyl-1-[(2r,3r,5r)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

(1s,3as,5ar,7r,8s,9ar,9br,11ar)-3a,8-dihydroxy-9a,11a-dimethyl-1-[(2r,3r,5r)-2,3,6-trihydroxy-5,6-dimethylheptan-2-yl]-7-{[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-5-one

C34H56O12 (656.3772)


   

methyl 3-[13-(decan-2-yl)-5,8,11-trihydroxy-3-(hydroxymethyl)-6-(1h-indole-3-carbonyl)-12-methyl-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-9-yl]propanoate

methyl 3-[13-(decan-2-yl)-5,8,11-trihydroxy-3-(hydroxymethyl)-6-(1h-indole-3-carbonyl)-12-methyl-2-oxo-1-oxa-4,7,10-triazacyclotrideca-4,7,10-trien-9-yl]propanoate

C34H48N4O9 (656.3421)


   

5,7-bis(acetyloxy)-10-[3-(furan-3-yl)-5-hydroxy-2-methylcyclopent-1-en-1-yl]-9-(2-methoxy-2-oxoethyl)-4,8,10-trimethyl-2-oxatricyclo[6.3.1.0⁴,¹²]dodecan-11-yl 2-methylbut-2-enoate

5,7-bis(acetyloxy)-10-[3-(furan-3-yl)-5-hydroxy-2-methylcyclopent-1-en-1-yl]-9-(2-methoxy-2-oxoethyl)-4,8,10-trimethyl-2-oxatricyclo[6.3.1.0⁴,¹²]dodecan-11-yl 2-methylbut-2-enoate

C36H48O11 (656.3196)


   

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16r,17r,18s)-4-(acetyloxy)-11-ethyl-8,9-dihydroxy-6,16,18-trimethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]ethanimidic acid

C35H48N2O10 (656.3309)


   

(1s,2s,4r,8r,9s,10z,12r)-11-({[(2r,3s,4r,5r)-4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate

(1s,2s,4r,8r,9s,10z,12r)-11-({[(2r,3s,4r,5r)-4-(acetyloxy)-3,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2e)-3-(1-methylimidazol-4-yl)prop-2-enoate

C35H48N2O10 (656.3309)


   

(2s)-5-carbamimidamido-2-[(1-hydroxy-4-{[(1r,2s,4r,5r,6r,7r,10s,11s,14s,16r)-5-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-4-oxobutylidene)amino]pentanoic acid

(2s)-5-carbamimidamido-2-[(1-hydroxy-4-{[(1r,2s,4r,5r,6r,7r,10s,11s,14s,16r)-5-hydroxy-7,11-dimethyl-6-(6-oxopyran-3-yl)-3-oxapentacyclo[8.8.0.0²,⁴.0²,⁷.0¹¹,¹⁶]octadecan-14-yl]oxy}-4-oxobutylidene)amino]pentanoic acid

C34H48N4O9 (656.3421)


   

2-[(5-hydroxy-6-{[1-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

2-[(5-hydroxy-6-{[1-hydroxy-1-(1-hydroxyethyl)-9a,11a-dimethyl-2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-4-methoxy-2-methyloxan-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl 3,4-dimethylpent-2-enoate

4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-(5-oxooxolan-3-yl)-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl 3,4-dimethylpent-2-enoate

C37H52O10 (656.356)


   

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-2-methylpropanimidic acid

n-[2-({[(1s,2r,3r,4s,5r,6s,8r,9s,10s,13s,16s,17r,18s)-11-ethyl-8,9-dihydroxy-4,6,16,18-tetramethoxy-11-azahexacyclo[7.7.2.1²,⁵.0¹,¹⁰.0³,⁸.0¹³,¹⁷]nonadecan-13-yl]methoxy}carbonyl)phenyl]-2-methylpropanimidic acid

C36H52N2O9 (656.3673)


   

1-[(3as,3br,5as,7r,8r,9as,9bs,11as)-7-{[(2r,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

1-[(3as,3br,5as,7r,8r,9as,9bs,11as)-7-{[(2r,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-8-hydroxy-9a,11a-dimethyl-3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethanone

C33H52O13 (656.3408)


   

4-(9-hydroxy-3-{5'-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-2,3'-dimethyl-[2,2'-bioxolan]-5-yl}-3,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl)-3-methoxy-2-methylpentanoic acid

4-(9-hydroxy-3-{5'-[6-hydroxy-6-(hydroxymethyl)-3,5-dimethyloxan-2-yl]-2,3'-dimethyl-[2,2'-bioxolan]-5-yl}-3,8-dimethyl-1,6-dioxaspiro[4.5]decan-7-yl)-3-methoxy-2-methylpentanoic acid

C35H60O11 (656.4135)


   

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3s)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-3,4-dimethylpent-2-enoate

(1r,2r,4s,5s,6s,10r,11s,12r,15r,16r,18s,19r)-4,18-bis(acetyloxy)-16-hydroxy-1,5,10,15-tetramethyl-6-[(3s)-5-oxooxolan-3-yl]-13-oxapentacyclo[10.6.1.0²,¹⁰.0⁵,⁹.0¹⁵,¹⁹]nonadec-8-en-11-yl (2e)-3,4-dimethylpent-2-enoate

C37H52O10 (656.356)


   

(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{[(2r,3s,4r,5r,6r)-6-{[(1s,3as,3br,7s,9ar,9bs,11ar)-3a-hydroxy-1-[(1s)-1-hydroxyethyl]-9a,11a-dimethyl-1h,2h,3h,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-5-hydroxy-4-methoxy-2-methyloxan-3-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C34H56O12 (656.3772)


   

(2s,4r,8r,9r,10z)-11-({[(2r,3r,4s,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2z)-3-(1-methylimidazol-4-yl)prop-2-enoate

(2s,4r,8r,9r,10z)-11-({[(2r,3r,4s,5r)-3-(acetyloxy)-4,5-dihydroxyoxan-2-yl]oxy}methyl)-8-isopropyl-12-methoxy-1,5-dimethyl-15-oxatricyclo[10.2.1.0⁴,⁹]pentadeca-5,10,13-trien-2-yl (2z)-3-(1-methylimidazol-4-yl)prop-2-enoate

C35H48N2O10 (656.3309)


   

(2r,3s,4r,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4s,4ar,8ar)-4-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl acetate

(2r,3s,4r,5r,6s)-6-{[(2s,3r,4s,5r,6r)-6-{[(1s,3r,4s,4ar,8ar)-4-[(3r)-3-hydroxy-3-methylpent-4-en-1-yl]-3,4,8,8a-tetramethyl-1,2,3,4a,5,6-hexahydronaphthalen-1-yl]oxy}-4,5-dihydroxy-2-methyloxan-3-yl]oxy}-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl acetate

C34H56O12 (656.3772)